Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124875 | 0.82 | PIK3CD (0.43) | PIK3CDHRH3ROCK2ROCK1CYP2D6 | |
| SCHEMBL3421117 | 0.79 | PIK3CD (0.41) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL23696545 | 0.79 | HRH3 (0.40) | PIK3CDHRH3 | |
| SCHEMBL18074011 | 0.78 | PIK3CD (0.45) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL3419598 | 0.78 | PIK3CD (0.44) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL9976596 | 0.78 | PIK3CD (0.45) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL1687229 | 0.76 | PIK3CD (0.42) | PIK3CDHRH3ROCK2ROCK1CYP2D6 | |
| SCHEMBL24607248 | 0.75 | PIK3CD (0.42) | PIK3CDHRH3KDM4E | |
| SCHEMBL21311463 | 0.75 | PIK3CD (0.45) | PIK3CDHRH3ROCK2ROCK1CYP2D6 | |
| SCHEMBL14706856 | 0.75 | PIK3CD (0.45) | PIK3CDHRH3ROCK2ROCK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020068-A1 | BACTERIAL TOPOISOMERASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885HRH3 3631/4885ROCK2 2938/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885HRH3 3631/4885ROCK2 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.